Article Versions Notes

Mangogna A, Cox MC, Ruco L, Lopez G, Belmonte B, Di Napoli A. Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. Diagnostics. 2020; 10(6):341. https://doi.org/10.3390/diagnostics10060341

Mangogna, Alessandro, Maria Christina Cox, Luigi Ruco, Gianluca Lopez, Beatrice Belmonte, and Arianna Di Napoli. 2020. "Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature" Diagnostics 10, no. 6: 341. https://doi.org/10.3390/diagnostics10060341

Mangogna, A., Cox, M. C., Ruco, L., Lopez, G., Belmonte, B., & Di Napoli, A. (2020). Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. Diagnostics, 10(6), 341. https://doi.org/10.3390/diagnostics10060341